Sarepta Therapeutics
SRPT
395 hedge funds and large institutions have $8.05B invested in Sarepta Therapeutics in 2023 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 123 increasing their positions, 140 reducing their positions, and 66 closing their positions.
81% more call options, than puts
Call options by funds: $655M | Put options by funds: $362M
14% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 66
0% more funds holding
Funds holding: 394 → 395 (+1)
0.15% less ownership
Funds ownership: 89.27% → 89.11% (-0.15%)
12% less repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 140
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
20% less capital invested
Capital invested by funds: $10.1B → $8.05B (-$2.04B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$280M |
| 2 |
Morgan Stanley
New York
|
+$183M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$79.9M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$65.7M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$50.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$317M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$97.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$67.9M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$67.6M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$56M |
SRPT Hedge Fund Activity: Q4 2023 in Review
395 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2023, worth a combined $8.05B — down 20% from $10.1B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new SRPT positions and 66 closed out — a net gain of 9 holders — while 123 added to existing stakes and 140 trimmed.
The largest buyer was Capital International Investors, adding an estimated $280M. The largest seller was JP Morgan Chase, cutting an estimated $317M.
- 395 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2023, up from 394 in Q3 2023.
- Funds reported $8.05B of Sarepta Therapeutics stock for Q4 2023, down 20% quarter-over-quarter.
- 75 funds opened new Sarepta Therapeutics positions in Q4 2023 and 66 closed out, a net change of +9 holders.
- The largest Sarepta Therapeutics buyer in Q4 2023 was Capital International Investors, an estimated $280M added.
- The largest Sarepta Therapeutics seller in Q4 2023 was JP Morgan Chase, an estimated $317M sold.
Based on aggregated 13F filings for Q4 2023.